Stroke

Featured Article

Patient With COPD, Smoking History Presents to ED With Sensory Loss

Patient With COPD, Smoking History Presents to ED With Sensory Loss

A 72-year-old man with a 50 pack-year smoking history and multiple comorbidities, including COPD, presents to the emergency department with left-sided hemiparesis and sensory loss.

Latest Features

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time

Using digital adherence devices to improve medication adherence in patients with atrial fibrillation may reduce the rate of ischemic strokes.

"Lone" Atrial Fibrillation: Lifestyle Management and Hybrid Procedures

"Lone" Atrial Fibrillation: Lifestyle Management and Hybrid Procedures

Optimal treatment strategies for lone atrial fibrillation have been unclear, but more technological advances and understanding of disease are propelling researchers forward.

"Lone" Atrial Fibrillation: Finding Optimal Treatment Strategies

"Lone" Atrial Fibrillation: Finding Optimal Treatment Strategies

Optimal treatment strategies for lone atrial fibrillation have been unclear, but more technological advances and understanding of disease are propelling researchers forward.

Reducing Neurologic Damage After Stroke With Ischemic Preconditioning

Reducing Neurologic Damage After Stroke With Ischemic Preconditioning

Ischemic preconditioning may provide neuroprotective effects that reduce stroke infarct size and improve recovery times.

Examining Cardiovascular Disease Risk Associated With Hepatitis C Infection

Examining Cardiovascular Disease Risk Associated With Hepatitis C Infection

Hepatitis C virus infection is a common cause of chronic liver disease worldwide and is associated with greater mortality.

Improving Stroke Diagnosis Accuracy: An Expert Interview

Improving Stroke Diagnosis Accuracy: An Expert Interview

An interview with David E. Newman-Toker, MD, PhD, on reducing the frequency of misdiagnoses.

Oral Anticoagulants After Intracranial Hemorrhage Reduced Mortality Risk in Afib

Oral Anticoagulants After Intracranial Hemorrhage Reduced Mortality Risk in Afib

A declining trend in ischemic events was associated with oral anticoagulant therapy after intracranial hemorrhage.

Transient Ischemic Attack Treatment Strategy Changes May Have Led to Lower CV Events Risk

Transient Ischemic Attack Treatment Strategy Changes May Have Led to Lower CV Events Risk

Risk for stroke and other vascular events at 90 days was 3.7% vs 12% to 20% in previous cohorts.

Left Atrial Appendage Closure: Exciting New Proposition or a Practically Non-Feasible Alternative?

Left Atrial Appendage Closure: Exciting New Proposition or a Practically Non-Feasible Alternative?

Occlusion of the left atrial appendage provides protection against thromboembolic stroke in patients with nonvalvular atrial fibrillation.

Factors Affecting Choice of Non-Vitamin K Antagonist Oral Anticoagulants

Factors Affecting Choice of Non-Vitamin K Antagonist Oral Anticoagulants

Choosing the right anticoagulant agent can be a challenge for many reasons, including cost, familiarity, drug interactions, and reversibility.

Latest News

Ischemic Stroke Risk Increased With Higher Platelet Reactivity Post-DES Implantation

Ischemic Stroke Risk Increased With Higher Platelet Reactivity Post-DES Implantation

High platelet reactivity was associated with an increased risk for ischemic stroke in patients who had undergone drug-eluting stent implantation.

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

Type 2 Diabetes Does Not Affect Pneumonia Incidence, Outcomes After Stroke

Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.

Rivaroxaban Use in Older Patients: Does Age Influence Safety, Efficacy?

Rivaroxaban Use in Older Patients: Does Age Influence Safety, Efficacy?

Data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients.

New Coagulation Monitoring Device Allows for Wireless Reporting of INR Results

New Coagulation Monitoring Device Allows for Wireless Reporting of INR Results

The system is intended for properly selected trained users ≥22 years of age who have been stabilized on anticoagulation with vitamin K antagonists for ≥6 weeks.

Stroke Risk Highest in Paroxysmal Afib With Greater Burden of Afib

Stroke Risk Highest in Paroxysmal Afib With Greater Burden of Afib

A greater burden of atrial fibrillation or flutter in patients with paroxysmal atrial fibrillation was associated with a higher risk for stroke when not taking anticoagulants.

FDA Approves Epoetin Alfa Biosimilar Retacrit

FDA Approves Epoetin Alfa Biosimilar Retacrit

The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

Andexxa, a recombinant modified human Factor Xa (FXa) protein, was approved under the FDA's Accelerated Approval pathway.

Anxiety May Increase Stroke, Intracranial Hemorrhage in Atrial Fibrillation

Anxiety May Increase Stroke, Intracranial Hemorrhage in Atrial Fibrillation

Anxiety may increase the risk for ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation.

Clopidogrel Plus Aspirin Reduces Recurrent Stroke Risk in Patients With Multiple Acute Infarctions

Clopidogrel Plus Aspirin Reduces Recurrent Stroke Risk in Patients With Multiple Acute Infarctions

Investigators assessed the impact of infarction patterns on the safety and effectiveness of dual antiplatelet therapy with clopidogrel and aspirin.

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.

Sign Up for Free e-Newsletters